Mar 2, 2020 SOURCE: PR NewsWire
AbbVie Inc. - Form 8.1 - Statement of Stock Purchase by Director
NORTH CHICAGO, Ill., March 2, 2020 /PRNewswire/ -- AbbVie issued the following forms today.
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF
THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY OFFERORS, OFFEREES OR PARTIES
ACTING IN CONCERT WITH THEM FOR THEMSELVES
OR FOR DISCRETIONARY CLIENTS
1.
KEY INFORMATION
Name of person dealing (Note 1)
AbbVie Inc.
---
Company dealt in
AbbVie Inc.
---
Class of relevant security to which the Common shares, par value
dealings being disclosed relate (Note 2) $0.01 per share
---
Date of dealing 28 February 2020
---
2.
INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
Long Short
Number (%) Number (%)
---
(1) Relevant securities N/A
---
(2) Derivatives (other than options) N/A
---
(3) Options and agreements to purchase/sell N/A
---
Total N/A
---
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A
Class of relevant security: Long Short
---
Number (%) Number (%)
(1) Relevant securities
---
(2) Derivatives (other than options)
---
(3) Options and agreements to purchase/sell
---
Total
---
3.
DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 5)
--- ---
Share buyback 2,452,782 $83.654
---
(b) Derivatives transactions (other than options transactions)
Product name,
Nature of transaction
Number of relevant securities
Price per unit
e.g. CFD
(Note 6)
(Note 7)
(Note 5)
---
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name,
Writing, selling,
Number of securities
Exercise
Type, e.g. American, Expiry
Option money
e.g. call option purchasing, to which the option price European etc. date paid/received
varying etc. relates (Note 7) per unit (Note 5)
--- ---
(ii) Exercising
Product name,
Number of securities
Exercise price per unit
e.g. call option (Note 5)
---
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction Details
Price per unit
(Note 8)
(if applicable) (Note 5)
---
4. OTHER INFORMATION
Agreements, arrangements or
understandings relating to options or
derivatives
---
Full details of any agreement,
arrangement or understanding between the
person disclosing and any other person
relating to the voting rights of any
relevant securities under any option
referred to on this form or relating to
the voting rights or future acquisition
or disposal of any relevant securities
to which any derivative referred to on
this form is referenced. If none, this
should be stated.
---
Is a Supplemental Form 8 attached? (Note 9) YES/NO
SQRT
Date of disclosure
2 March 2020
---
Contact name Steven L. Scrogham
---
Telephone number
847-938-6166
---
Name of offeree/offeror with which acting in concert
AbbVie Inc.
---
Specify category and nature of acting in concert status
AbbVie Inc.
---
1.
KEY
INFORMATION
Name of person dealing (Note 1) Richard Gonzalez
---
Company dealt in
AbbVie Inc.
---
Class of relevant security to which the dealings being disclosed relate (Note 2) Common shares, par value
$0.01 per share
---
Date
of
dealing 21 February 2020
---
2.
INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
Long Short
Number (%) Number (%)
---
(1) Relevant securities 523,561 Common Shares
(0.0004%)
---
(2)
Derivatives
(other
than
options) N/A
---
(3) Options and agreements to purchase/sell 1,161,286 options
(0.0008%)
---
Total 1,684,847 (0.0011%)
---
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A
Class of relevant security: Long Short
---
Number (%)
Number (%)
(1) Relevant securities
---
(2)
Derivatives
(other
than
options)
---
(3) Options and agreements to purchase/sell
---
Total
---
3.
DEALINGS (Note 4)
(a) Purchases and sales
---
Purchase/sale
Number of relevant securities
Price per unit (Note 5)
--- ---
Issue of common shares
pursuant to AbbVie equity
award plans
200,262 common shares $0
--- ---
Gift of common shares
3,675 common shares $0
--- ---
(b) Derivatives transactions (other than options transactions)
Product name,
Nature of transaction
Number of relevant securities
Price per unit
e.g.
CFD
(Note 6)
(Note 7)
(Note 5)
---
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
---
Product Writing,
selling, Number
of
name, securities
Exercise Type,
e.g. Expiry Option
money
e.g. to
which
call the
option
option
purchasing,
price
American,
date
paid/received
varying etc.
relates (Note 7)
European etc.
per unit (Note 5)
--- ---
(ii) Exercising
---
Product name,
Number of securities
Exercise price per unit
e.g.
call
option (Note 5)
---
(d) Other dealings (including transactions in respect of new securities) (Note 4)
---
Nature
of
transaction Details Price
per
unit
(Note 8)
(if applicable) (Note 5)
---
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
---
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is
referenced. If none, this should be stated.
---
Is a Supplemental Form 8 attached? (Note 9) YES/NO
SQRT
Date of disclosure
2 March 2020
---
Contact
name Steven L. Scrogham
---
Telephone
number
847-938-6166
---
Name
of
offeree/offeror
with
which
acting
in
concert
AbbVie Inc.
---
Specify category and nature of acting in concert status Director of AbbVie Inc.
---
1.
KEY INFORMATION
Name of person dealing (Note 1) Richard Gonzalez
---
Company dealt in
AbbVie Inc.
---
Class of relevant security to which the Common shares, par value
dealings being disclosed relate (Note 2) $0.01 per share
---
Date of dealing 28 February 2020
---
2.
INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
Long Short
Number (%) Number (%)
---
(1) Relevant securities 434,843 Common Shares
(0.0004%)
---
(2) Derivatives (other than options) N/A
---
(3) Options and agreements to purchase/sell 1,161,286 options
(0.0008%)
---
Total 1,596,128 (0.0011%)
---
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A
Class of relevant security: Long Short
---
Number (%) Number (%)
(1) Relevant securities
---
(2) Derivatives (other than options)
---
(3) Options and agreements to purchase/sell
---
Total
---
3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale
Number of relevant securities
Price per unit (Note 5)
---
Withholding of common
shares to satisfy tax
obligations
88,719 common shares $0
---
(b) Derivatives
transactions (other than
options transactions)
Product name,
Nature of transaction
Number of relevant securities
Price per unit
e.g. CFD
(Note 6)
(Note 7)
(Note 5)
---
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name,
Writing, selling,
Number of securities
Exercise
Type, e.g. American, Expiry
Option money
e.g. call option purchasing, to which the price European etc. date paid/received
varying etc. option relates (Note 7) per unit (Note 5)
--- ---
(ii) Exercising
Product name, Number of securities
Exercise price
e.g. call option per unit (Note 5)
---
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction
Details
Price per unit
(Note 8)
(if applicable) (Note 5)
---
4. OTHER INFORMATION
Agreements, arrangements or
understandings relating to options or
derivatives
---
Full details of any agreement,
arrangement or understanding between the
person disclosing and any other person
relating to the voting rights of any
relevant securities under any option
referred to on this form or relating to
the voting rights or future acquisition
or disposal of any relevant securities
to which any derivative referred to on
this form is referenced. If none, this
should be stated.
---
Is a Supplemental Form 8 attached? (Note 9) YES/NO
SQRT
Date of disclosure
2 March 2020
---
Contact name Steven L. Scrogham
---
Telephone number
847-938-6166
---
Name of offeree/offeror with which acting in concert
AbbVie Inc.
---
Specify category and nature of acting in concert status Director of AbbVie Inc.
---
View original content:http://www.prnewswire.com/news-releases/abbvie-inc---form-8-1---statement-of-stock-purchase-by-director-301014871.html
SOURCE AbbVie
